Συγγραφείς:
Vassilakopoulos, T.P.
Piperidou, A.
Hadjiharissi, E.
Panteliadou, A.-K.
Panitsas, F.
Vassilopoulos, I.
Variamis, E.
Boutsis, D.
Michail, M.
Papageorgiou, S.
Tsourouflis, G.
Dimou, M.
Karakatsanis, S.
Kalpadakis, C.
Stavroyianni, N.
Katodritou, E.
Kotsopoulou, M.
Kotsianidis, I.
Verigou, E.
Hatzimichael, E.
Leonidopoulou, T.
Xanthopoulos, V.
Panayiotidis, P.
Konstantopoulos, K.
Dimopoulos, M.-A.
Karmiris, T.
Batsis, I.
Papaioannou, M.
Pangalis, G.A.
Angelopoulou, M.K.
Λέξεις-κλειδιά:
bleomycin; brentuximab vedotin; carboplatin; cisplatin; cyclophosphamide; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; cytarabine; dacarbazine; dexamethasone; doxorubicin; etoposide; gemcitabine; ifosfamide; prednisolone; prednisone; procarbazine; rituximab; vinblastine; vincristine; vindesine; vinorelbine tartrate; antineoplastic agent, adult; autologous stem cell transplantation; cancer incidence; cancer patient; cancer radiotherapy; cancer regression; classical Hodgkin lymphoma; clinical article; cohort analysis; female; follow up; human; large cell lymphoma; Letter; male; mediastinum cancer; multiple cycle treatment; primary mediastinal large B cell lymphoma; priority journal; diffuse large B cell lymphoma; factual database; Hodgkin disease; mediastinum tumor; pathology; prognosis; survival rate, Adult; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Female; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Prognosis; Survival Rate
